WEST PHARMACEUTICAL SERVICES INC

West Pharmaceutical Services, Inc. (NYSE: WST) operates as a leading global manufacturer of technologically advanced, high-quality integrated containment and delivery systems for injectable drugs and healthcare products. The company maintains its website at www.westpharma.com and serves biologic, generic, pharmaceutical, diagnostic, and medical device companies worldwide.

The company operates through two primary business segments. The Proprietary Products segment, representing approximately 73 percent of the workforce, offers elastomers and primary containment solutions, drug delivery devices, integrated systems, and analytical laboratory services. This segment manufactures stoppers and seals for injectable packaging systems, syringe and cartridges components, vials, plungers, and self-injection devices. The company also provides films, coatings, washing, vision inspection, and sterilization processes. The Contract-Manufactured Products segment focuses on the design, manufacture, and automated assembly of complex devices for pharmaceutical, diagnostic, and medical device customers, utilizing technologies including multi-component molding, ultrasonic welding, and clean room molding.

West employs approximately 10,800 people globally, distributed across North America (43 percent), Europe (42 percent), Asia Pacific (12 percent), and South America (3 percent). The company maintains manufacturing facilities across North and South America, Europe, and Asia, with affiliated companies in Japan and Mexico. International operations generated 56.7 percent of consolidated net sales in 2025, reflecting the company's substantial global presence.

The company's product portfolio includes the proprietary Crystal Zenith brand, a registered trademark licensed from Daikyo Seiko, Ltd., which represents a significant innovation in drug containment solutions. West differentiates itself through integrated solutions combining primary packaging components, containment solutions, and drug delivery devices with pre-approval support, engineering development, regulatory expertise, and technical support. The company's top ten customers accounted for 47.6 percent of consolidated net sales in 2025, with one customer representing 15.8 percent of net sales across both reportable segments.

West maintains robust intellectual property protections through owned and licensed patents, trademarks, and proprietary technologies. The company competes with firms including Datwyler and Aptar in proprietary products and Phillips Medisize and other contract manufacturers in device assembly, differentiating through quality, regulatory compliance, scientific expertise, and global manufacturing capabilities.